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352 The Journal of Thoracic and Cardbjective: Cardiac surgery induces a systemic inflammatory activation, which in
evere cases is associated with peripheral vasodilation and hypotension. Cardiotomy
uction blood contains high levels of inflammatory mediators, but the effect of
ardiotomy suction blood on the vasculture is unknown. We investigated the effect
f cardiotomy suction blood on systemic vascular resistance in vivo and whether
ell-saver processing of suction blood affects the vascular response.
ethods: Twenty-five patients undergoing coronary surgery (mean age, 68  2
ears; 80% men) were included in a prospective randomized study. The patients
ere randomized to retransfusion of cell-saver processed (n  13) or cell-saver
nprocessed (n  12) suction blood during full cardiopulmonary bypass. Mean
rterial blood pressure was continuously registered during retransfusion, and sys-
emic vascular resistance was calculated. Plasma concentrations of tumor necrosis
actor , interleukin 6, and complement factor C3a were measured in suction blood.
esults: Retransfusion of cardiotomy suction blood induced a transient reduction in
ystemic vascular resistance in all patients. The peak reduction was significantly less
ronounced in the group receiving cell-saver processed blood (12%  2% vs
28% 3%, P .001). There was a significant correlation between tumor necrosis
actor  concentration in retransfused cardiotomy suction blood and peak reduction
f systemic vascular resistance (r  0.60, P  .002).
onclusions: The results suggest cardiotomy suction blood is vasoactive and might
nfluence vascular resistance and blood pressure during cardiac surgery. The ob-
erved vasodilation is proportional to the inflammatory activation of suction blood
nd can be reduced by processing suction blood with a cell-saving device before
etransfusion.
ardiac surgery induces a systemic inflammatory response characterized by
complement activation and release of proinflammatory and anti-inflammatory
cytokines.1,2 The inflammatory response might be subclinical but is, in
ost severe forms, associated with peripheral vasodilation and hypotensio3-6
ustained hypotension can result in insufficient end-organ perfusion and isch
omplications.
Cardiotomy suction (CS) during cardiopulmonary bypass (CPB) is used to
aintain an appropriate hemoglobin concentration and to reduce the need for
omologous blood transfusions. However, there is a pronounced inflammatory
ctivity in CS blood, and retransfusion of CS blood has therefore been suggested to
ontribute to the postoperative inflammatory response.7-11 Inflammatory mediators,
uch as cytokines and complement split products, have vasoactive properties12-14
nd CS blood might therefore influence vascular resistance. However, to our
nowledge, no previous investigation has studied whether CS blood has hemody-
amic effects when retransfused. Our first aim was thus to investigate potential
emodynamic effects of CS blood in vivo, and in addition, we sought to investigate
hether potential effects could be related to concentrations of inflammatory medi-
iovascular Surgery ● June 2006
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Ptors in CS blood. Finally, we wanted to study whether
otential hemodynamic effects are reduced if the CS blood
s processed with a cell-saver before retransfusion. For these
urposes, a prospective randomized study was performed in
atients undergoing coronary artery bypass grafting (CABG)
ith CPB.
atients and Methods
atients
nclusion criteria were as follows: age of 40 to 80 years, 2- or
-vessel coronary disease with angina pectoris and appropriate
oronary anatomy for CABG, left ventricular ejection fraction of
reater than 40%, and no other significant disorders. Exclusion
riteria were as follows: preoperative use of steroids or nonsteroi-
al anti-inflammatory drugs, intraoperative administration of va-
oactive or anti-inflammatory drugs, and signs of significant pe-
ipheral arterial disease.
The study group consisted of 25 patients with a mean age of
8  2 years, 80% of whom were men. Patient characteristics are
hown in Table 1. All patients were operated on with CPB
esearch Ethics Committee of the Medical Faculty, University of
othenburg, approved the study protocol.
linical Management
he patients were premedicated with flunitrazepam and morphine-
copolamine. Anesthesia was induced with 3 to 5 mg/kg thiopen-
al, followed by 0.1 mg/kg pancuronium. Fentanyl was adminis-
ered in incremental doses up to a total amount of 8 to 10 g/kg
efore sternotomy. The patients were normoventilated with oxy-
en in air (fraction of inspired oxygen, 0.4-0.5), and enflurane was
sed as an inhalational agent both before and after CPB. Propofol
as administered during CPB. Before cannulation, heparin (300
U/kg; Lövens, Ballerup, Denmark) was administered and supple-
ented as required to maintain an activated clotting time of more
han 480 seconds. The extracorporeal circuit was primed with
pproximately 1700 mL of Ringer-acetate (Fresenius-Kabi, Upp-
ala, Sweden), 200 mL of mannitol (Fresenius-Kabi), 100 mL of
ribonate (Fresenius-Kabi), and 7500 IU of heparin. CPB was
erformed with a hollow-fiber membrane oxygenator. A hard-shell
eservoir (with blood-air interface) with separate chambers for
enous return and CS blood was used (D 903 Avant; Dideco,
irandola Modena, Italy). The reservoir design makes it possible
o collect CS blood and allows blood sampling before the content
s returned to the venous reservoir. Aprotinin was not used.
The operations were performed with a standard nonpulsatile
Abbreviations and Acronyms
CABG coronary artery bypass grafting
CPB  cardiopulmonary bypass
CS  cardiotomy suction
IL  interleukin
SVR  systemic vascular resistance
TNF  tumor necrosis factorPB technique with moderate hypothermia (nasopharyngeal tem- o
The Journal of Thoracice
erature, 34°C) and hemodilution (hematocrit, 20% to 30%). A
tandard flow of 2.4 L · min1 · m2 was used. Cardioprotection
as achieved with cold blood cardioplegia. No topical cooling was
sed. Weaning off CPB was performed after rewarming to a rectal
emperature of at least 36°C.
tudy Protocol and Analyses
he patients were randomly allocated into 2 groups. In the first
roup CS blood was evacuated from the reservoir and processed in
cell-saver device (autoLog; Medtronic, Minneapolis, Minn) be-
ore retransfusion (n  13). In the second group CS blood was
etransfused without further processing (n  12). The cell-saver
roduced approximately 135 mL of washed, packed red blood
ells. Ringer-acetate was added to the processed blood to maintain
retransfusion volume and hematocrit value comparable with
hose of the unprocessed group. All CS blood was retransfused
uring full CPB immediately before weaning by opening the hatch
etween the CS reservoir chamber and the venous return reservoir.
Concentrations of the proinflammatory cytokines tumor necro-
is factor (TNF)  and interleukin (IL) 6 and complement factor
3a were measured in the separate CS reservoir before and after
ell-saver processing. Samples for cytokine and complement anal-
ses were collected into tubes with ethylenediamine tetraacetic
cid and placed immediately on ice. The aliquots were centrifuged
mmediately, and the resultant plasma was stored at 70°C until
nalysis. TNF-, IL-6, and C3a levels were determined with
ommercially available enzyme-linked immunosorbent assay kits
y using double-antibody enzyme-linked immunosorbent assays,
ccording to the manufacturer’s instructions. The following assays
ere used: TNF- and IL-6, R&D systems; C3a, Quidel (San
iego, Calif). Hemoglobin content and hematocrit value were also
nalyzed in CS blood before retransfusion.
Mean arterial blood pressure was continuously registered from
he arterial line and stored with 200 samples per second by using
computer technique (Acknowledge; BioPac Systems, Santa Bar-
ara, Calif). An investigator blinded to group affiliation analyzed
he files.
alculations
ystemic vascular resistance (SVR) was calculated according to
he formula SVR  80  MAP⁄cardiac output, where cardiac
ABLE 1. Preoperative and perioperative variables (mean 
tandard error of the mean)
Cell-saver
group
Unprocessed
group P value
13 12
ge (y) 67 2 69  2 .33
ex (M/F) 10/3 10/2 .54
jection fraction 0.53 0.03 0.52 0.04 .85
ortic clamp time (min) 45 5 41  4 .53
PB time (min) 90 8 80  6 .45
o. of grafts 3.5 0.3 3.1 0.3 .41
PB, Cardiopulmonary bypass.utput equals the CPB flow rate. Plasma concentrations of TNF-,
and Cardiovascular Surgery ● Volume 131, Number 6 1353
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CSPL-6, and C3a in suction blood were corrected for hematocrit by
elating measurements to a standard hematocrit value of 40%
ccording to the following formula:
Corrected concentrationMeasured concentration
 (Standard hematocrit ⁄ Measured hematocrit).7
tatistics
he nonparametric Mann-Whitney U test (continuous variables)
nd the Fisher exact test (categoric variables) were used to com-
are the groups. Differences within a group were compared with
he paired nonparametric Wilcoxon test. Comparisons were made
oth with percentage change from baseline and with absolute values.
orrelation was analyzed with the Spearman rank sum test. All the
esults are expressed as the mean  standard error of the mean.
esults
linical Course
ne patient in the cell-saver group had a perioperative
troke. All other patients recovered normally after surgical
ntervention and were discharged from the hospital within 7
ays. None of the patients received transfusion of homolo-
ous blood, predonated autologous blood, or any other
lood product during the study.
aseline Variables
here were no statistically significant differences between
he cell-saver group and the unprocessed group with respect
o age, sex, ejection fraction, aortic clamp time, or number
igure 1. Representative sample of mean arterial pressure during
etransfusion of unprocessed cardiotomy suction blood.f grafts (Table 1). .
354 The Journal of Thoracic and Cardiovascular Surgery ● JunS Blood and SVR
he mean volume of collected CS blood during the opera-
ion was 477  36 mL. The mean volume of retransfused
S blood was 403 17 mL, and the mean hematocrit value
as 15%  2%. The mean arterial pressure before retrans-
usion was 67 3 mm Hg. Rapid retransfusion of CS blood
nduced a transient reduction in SVR immediately after
etransfusion in all patients (Figures 1 and 2). The 
ime to minimum SVR was 42  2 seconds.
nflammatory Mediators and SVR
lasma concentrations of TNF-, IL-6, and C3a were sig-
ificantly increased in unprocessed CS blood compared
ith systemic plasma concentrations at the same time point
TNF-: 280%  154%, P  .001; IL-6: 1268% 
45%, P  .001; C3a: 473%  136%, P  .001). The
bsolute values were 10.1  2.4 versus 4.5  1.1 pg/mL
P  .010) for TNF-, 600  174 versus 100  46 pg/mL
P  .001) for IL-6, and 5294  953 versus 1107  107
g/mL (P  .001) for C3a.
There were statistically significant correlations be-
ween TNF- concentrations in retransfused CS blood
nd % SVR (r  0.60, P  .002, y  0.15 to 0.02x;
igure 3) and between C3a and  % SVR (r  0.43, P 
043, y  0.14 to 6  105x). No correlation between
L-6 and % SVR was detected (r  0.22, P  .31).
ffects of Cell-saver Processing
Perioperative bleeding and retransfusion. The mean
olume of collected CS blood during the operation was
igher in the cell-saver group (551  55 mL) compared
ith that in the unprocessed group (397  37 mL, P 
igure 2. Relative changes in systemic vascular resistance
SVR) during retransfusion of cell-saver processed or cell-saver
nprocessed cardiotomy suction blood (mean standard error of
he mean). There was a significant difference between the 2
roups (P  .001).009). The mean volume of retransfused CS blood did not
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Piffer between the groups (401  1 mL in the cell-saver
roup and 405 36 mL in the unprocessed group, P .25).
here was no significant difference in hematocrit values
f the retransfused blood between the groups (17% 2% in
he cell-saver group and 14%  2% in the unprocessed
roup, P  .20).
Inflammatory activation in CS blood. Cell-saver pro-
essing significantly reduced concentrations of TNF-
38%  11%, P  .012) and C3a (70%  14%, P 
016) in CS blood. In absolute values TNF- levels de-
reased from 7.5  2.5 to 3.5  1.6 pg/mL (P  .012) and
3a levels decreased from 4337  1087 to 1757  913
g/mL (P  .021). IL-6 levels tended to decrease (19% 
4%, P .27), from 633 315 to 229 81 pg/mL (P .13).
Hemodynamic effects. Baseline SVR (immediately be-
ore retransfusion of CS blood) was comparable between
he cell-saver group and the unprocessed group (1086  82
s 1115  77 dynes · s1 · cm5, P  .58).
During retransfusion of CS blood, the vasodilation was
ess pronounced in the group receiving cell-saver processed
lood compared with that seen in the group receiving
nprocessed blood (SVR  140  34 vs 326  50
ynes · s1 · cm5, P  .006). The relative reduction in
 SVR is depicted in Figure 2.
iscussion
he main findings in the present study were as follows: (1)
apid retransfusion of CS blood induced a transient reduc-
ion in SVR; (2) the reduction in SVR was proportional to
he inflammatory activation in CS blood; and (3) processing
uction blood with a cell-saving device before retransfusion
igure 3. Correlation between plasma levels of TNF- in retrans-
used cardiotomy suction blood and relative changes in systemic
ascular resistance.educed the effect on the vasculature. s
The Journal of Thoracicnflammation and Hemodynamics
ardiac surgery induces an inflammatory response. The in-
ammatory response can result in postoperative complications,
uch as prolonged ventilation and renal failure,6,15-17 and h a
lso been associated with myocardial injury.18 In its mos
evere forms, the systemic inflammatory response is asso-
iated with peripheral vasodilation and hypotension,1-6,13,19
nd the inflammatory activation has also been connected
ith a vasoplegic syndrome after cardiac surgery.3-5
Systemic levels of cytokines and complement factors are
educed during and early after CABG when CS is dis-
arded,7 which demonstrates that CS contributes to 
nflammatory activation during and after cardiac surgery.
S blood contains high levels of cytokines (IL-1, IL-6, and
NF-) and complement split factors (C3a and sC5b-
),7,10,11,20-23 which a l l have vasoactive properties.12-14 The-
retically, CS blood can thus contribute to perioperative
asodilation, but to our knowledge, this issue has not pre-
iously been investigated.
We hypothesized that CS blood is vasoactive and estab-
ished an in vivo method to investigate the effect in patients
ndergoing CABG with CPB. CS blood was collected in a
eparate reservoir during the operation and retransfused
mmediately before weaning of CPB during continuous
lood pressure registration. The heart was completely un-
oaded, and thus a potential reduction in mean arterial pressure
an be regarded as an effect caused by vasodilation. From the
easured arterial pressure, the change in SVR was calcu-
ated. Retransfusion of unprocessed CS blood in this model
aused a prompt reduction in systemic resistance (28%),
hich thus demonstrates the vasoactive properties of CS
lood. It is conceivable that this is an effect of the inflam-
atory activity in CS blood because the magnitude of the
eduction in SVR correlated to the concentrations of TNF-
n CS blood (Figure 3) and, to a lesser degree, to
NF-, IL-6, and C3a are not only markers of inflammation
ut also have their own important pathophysiologic ef-
ects.24,25 TNF- increases stress hormone release and ne-
rophil adhesion, causes myocardial depression, and stimu-
ates production of other cytokines, such as IL-6 and IL-8.
NF- has also vasoactive properties and has been demon-
trated to stimulate production of inducible nitric oxide
ynthase.2,26 One might thus speculate that the mar
mmediate effect of CS blood on SVR is mediated by nitric
xide.
The hemodynamic effects of CS blood might be attenu-
ted or even absent if the suction blood is retransfused over
more extensive period. However, when we designed the
resent study, it was not known whether CS blood had any
emodynamic effects at all. The study was therefore inten-
ionally designed to investigate the potential hemodynamic
ffects of CS blood in an artificial experimental set up with
udden retransfusion. If this design demonstrates hemody-
and Cardiovascular Surgery ● Volume 131, Number 6 1355
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CSPamic effects, it would motivate further studies with different
rotocols and hypotheses to study the clinical importance.
ell-saver Processing
ell-saver processing reduces the amount of inflammatory
ediators in CS blood significantly.8,27,28 However, de-
ending on the device, 5% to 20% of cytokines remain after
rocessing.27,28 In the present investigation cell-saver p-
essing decreased TNF- and C3a concentrations in CS
lood and reduced the systemic vasodilation by approxi-
ately 60% compared with unwashed blood (12% vs 28%).
he subtotal reduction of inflammatory substances might
xplain why the reduction in SVR in the present study was
ot entirely abolished in the cell-saver group. Alternatively,
ther properties of the retransfused blood volume (viscosity
nd temperature) that are not influenced by cell-saver pro-
essing might have an effect on vascular resistance.
imitations
VR can be influenced by different factors (eg, sympathetic
ctivation, drugs, blood viscosity, and temperature).29,30
onsidering this, there are some limitations in the study
esign that need to be discussed. The hematocrit value of
he retransfused blood was lower than that in the patient,
ndicating a lower viscosity. This might partly explain the
eduction in SVR in both groups. However, because neither
he hematocrit value nor the retransfused volume (constant
ump flow) differed significantly between the processed and
he unprocessed groups, this does not explain the marked
ntergroup difference caused by cell-saver processing. The
emperature of the retransfused blood was not measured
pecifically but is probably somewhat lower than in the
ystemic circulation and similar between the 2 groups.
The dilution of the CS blood in the cell-saver group after
rocessing can be debated. The rationale was as mentioned
bove, that it has been shown that blood viscosity can
nfluence SVR.29 To avoid differences in viscosity, 
hose to replace the plasma with Ringer-acetate in the
ell-saver group. One might argue that this was artificial and
ight have influenced the results. However, a pilot study was
erformed with the same experimental set up as in the present
tudy, and in this model infusion of a comparable amount of
inger-acetate did not influence vascular resistance.
Another issue is whether stasis of the CS blood in the
eservoir might affect the levels of inflammatory media-
ors. This cannot be ruled out with the present study
esign, but it should be emphasized that the blood was
ontinuously collected during CPB, and therefore the
nal content in the reservoir is a mix of suction blood
ollected over approximately 45 minutes. Again, the han-
ling was identical in both groups, and this cannot ex-
lain intergroup differences.
356 The Journal of Thoracic and Cardiovascular Surgery ● Junlinical Implications
S blood is often suctioned directly into the venous reser-
oir and retransfused continuously, diluted in the circulating
lood volume. Vascular effects of CS blood might thus be
nsignificant or even undetectable in routine cardiac sur-
ery. However, in high-risk patients or in patients undergo-
ng long or complicated operations with extensive intraop-
rative bleeding, the observed effect of CS blood on SVR
ight be of greater importance. Accordingly, the results of
he present study do not indicate that the present handling of
S blood should be revised but propose that the importance
f retransfusion of CS blood is investigated in studies with
linical end points.
The observation that processing CS blood with a cell-
aving device significantly reduced the effect on SVR sup-
orts, at first sight, the use of cell-saving devices periopera-
ively, at least when considerable intraoperative bleeding
an be expected. However, cell-saver processing might also
ave potential harmful effects on the blood, such as bleed-
ng diathesis related to loss of platelets and coagulation
roteins, which might counteract beneficial effects. Again,
linical studies are warranted.
We appreciate the skilful assistance in laboratory analyses by
aria Tylman.
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